监管与产业情报（Pharma-Intel）· Oncoimmunology·· 4 天前评分38
<think>
Clinical outcomes and blood-based biomarkers across two SABR-treated metastatic settings: oligoprogression under immune checkpoint inhibition and oligometastatic disease
导读
The user wants me to act as a senior biomedical editor and complete two tasks。
来源：监管与产业情报（Pharma-Intel） · doi.org